Brexpiprazole as an adjunctive treatment to buprenorphine to treat opioid use disorder
Ended Cooperative Agreement Awarded Last action
- Award ID
- UG3DA051383
- Recipient
-
Otsuka Pharmaceutical Development & Commercialization, Inc. UEI N4TCZ8N86B21
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,023,155
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- Place of performance
- New Jersey, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $4,023,155 |
Quick answers
Who received award UG3DA051383?
UG3DA051383 was awarded to Otsuka Pharmaceutical Development & Commercialization, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2020.
How much is award UG3DA051383 worth?
$4,023,155 has been obligated on UG3DA051383.
Which agency awarded UG3DA051383?
National Institute on Drug Abuse (National Institutes of Health) awarded UG3DA051383, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award